Sionna Therapeutics, Inc. (SION)
NASDAQ:SION
SION Stock Chart & Stats
$36.95
$0.55(1.26%)
At close: 4:00 PM EST
$36.95
$0.55(1.26%)
Day’s Range― - ―
52-Week Range$7.26 - $45.00
Previous CloseN/A
Volume33.51K
Average Volume (3M)299.13K
Market Cap
$1.66B
Enterprise Value$1.61B
Total Cash (Recent Filing)$235.88M
Total Debt (Recent Filing)$8.68M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
May 18, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding44,998,074
10 Day Avg. Volume346,705
30 Day Avg. Volume299,130
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.04K
Enterprise Value/Ebitda-21.43
Forecast
1Y Price Target
$51.17Price Target Upside38.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Combination EfficacyPreclinical and early combination data indicate that repairing the NBD1 structural defect alongside standard modulators can produce CFTR channel activity approaching normal levels, supporting potential additive clinical benefit.
Mechanism InnovationIdentification of small molecules that directly bind and stabilize the NBD1 domain demonstrates a novel mechanism that could correct the CFTR folding defect and restore protein function.
Translational Assay ValidationCalibration of the company's CF HBE assay to an industry-standard model increases confidence that preclinical activity and biomarker changes will translate to clinical outcomes and guide dose selection.
Bears Say
Clinical Trial Design RiskA small, short-duration Phase 2a crossover study increases reliance on sweat chloride as the primary efficacy measure, which could leave respiratory benefit uncertain if biomarker changes are minimal.
Funding And Cost PressuresRising operating expenses and high cash burn heighten funding risk and may necessitate future financing that could dilute existing shareholders and pressure the stock.
Target RiskConcerns that the ATP-binding pocket within NBD1 is unsuitable for small-molecule targeting raise uncertainty about whether direct NBD1 binders can improve channel function without unintended inhibitory effects.
Sionna Therapeutics, Inc. News
SION FAQ
What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $7.25 and its highest was $45.00 in the past 12 months.
What is Sionna Therapeutics, Inc.’s market cap?
Sionna Therapeutics, Inc.’s market cap is $1.66B.
When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
Sionna Therapeutics, Inc.’s upcoming earnings report date is May 18, 2026 which is in 39 days.
How were Sionna Therapeutics, Inc.’s earnings last quarter?
Sionna Therapeutics, Inc. released its earnings results on Mar 19, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.539 by $0.079.
Is Sionna Therapeutics, Inc. overvalued?
According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued.
Does Sionna Therapeutics, Inc. pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
What is Sionna Therapeutics, Inc.’s EPS estimate?
Sionna Therapeutics, Inc.’s EPS estimate is -0.52.
How many shares outstanding does Sionna Therapeutics, Inc. have?
Sionna Therapeutics, Inc. has 44,998,074 shares outstanding.
What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
Sionna Therapeutics, Inc. reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.539. Following the earnings report the stock price went up 3.169%.
Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sionna Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.17 (38.48% Upside)
$51.17 (38.48% Upside)
Blogger Sentiment
Bullish
SION Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 540.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
274.92%
12-Months-Change
Fundamentals
Return on Equity
-22.87%
Trailing 12-Months
Asset Growth
76.54%
Trailing 12-Months
Company Description
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
SION Stock 12 Month Forecast
Average Price Target
$51.17
▲(38.48% Upside)
Technical Analysis
Stoke Therapeutics
―
Vir Biotechnology
―
Immatics
―
Tango Therapeutics
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
Currently, No data available
---